TrianglePembrolizumab + Single-Agent… (NCT04297605)
Pembrolizumab + Single-Agent Chemotherapy trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2) (NCT04297605). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for locally advanced or metastatic non-small cell lung cancer, in adults whose daily activity is limited, called performance status 2.
The idea: pair immunotherapy with a single chemotherapy drug. Pembrolizumab is given with either pemetrexed or nab-paclitaxel, every 21 days, as first treatment. The study enrolls patients with stage three C or stage four disease.
This pilot phase 1 study asks whether the combination is tolerable, and plans 60 patients. At the University of Rochester in New York, Megan Baumgart leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.